29.02MMarket Cap-458P/E (TTM)
0.770High0.750Low169.48KVolume0.750Open0.750Pre Close127.76KTurnover0.79%Turnover RatioLossP/E (Static)38.13MShares1.71052wk High0.28P/B16.31MFloat Cap0.73452wk Low--Dividend TTM21.43MShs Float43.070Historical High--Div YieldTTM2.67%Amplitude0.734Historical Low0.753Avg Price1Lot Size
Bolt Biotherapeutics Stock Forum
Bolt Biotherapeutics (BOLT) shares were nearly 32% lower in premarket activity Wednesday following the company's announcement late Tuesday that it will stop the development of trastuzumab imbotolimod, BDC-1001, and has trimmed its workforce by about 50%.
The company said the BDC-1001 program is not expected to meet its pre-defined success criteria and it will now focus on developing its other cancer pipeline, which includes a first-in...
It has healthy balance sheet (25% debt) and income, believe it's under value with $1 now...
• $Credicorp(BAP.US)$ : Citigroup Upgrades to Buy from Neutral - PT $161 (from $128)
• $Bank of New York Mellon(BK.US)$ : Citigroup Upgrades to Buy from Neutral
• $CommScope(COMM.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $17 (from $11)
• $Domino's Pizza(DPZ.US)$ : UBS Upgrades to Buy from Neutral - PT $385 (from $430)
• $Gilead Sciences(GILD.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $80 (fr...
• $Clovis Oncology(CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US)$ +9.5% (secured a battery sa...
$Inhibikase Therapeutics(IKT.US)$
ATLANTA, Mar. 2, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference.
https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-hc-wainwright--co-global-life-sciences-virtual-conference-301238073.html
https://newsfilter.io/a/94932b8a928e6b7df704caecd241da83
...
No comment yet